Aarti Drugs Names Adhish Patil Managing Director for 5-Year Term

MUMBAI, India — Pharmaceutical manufacturer Aarti Drugs Limited announced on July 31, 2026, that its Board of Directors has approved the appointment of Chief Financial Officer Adhish P. Patil as Managing Director for a five-year term, effective October 1, 2026.

The board meeting, held on Friday, July 31, 2026, outlined a major executive succession plan. The restructuring follows the decision of founding leader Prakash M. Patil to retire as Chairman, Managing Director, and Chief Executive Officer at the close of business hours on September 30, 2026, ahead of his scheduled term end in May 2027, to facilitate an orderly leadership transition. Under the approved transition, current Managing Director Rashesh C. Gogri will assume the role of Chairman starting October 1, 2026, while retaining his duties as Managing Director alongside Adhish Patil.

Strategic Executive Succession at Aarti Drugs

Adhish P. Patil, who has served as Chief Financial Officer since April 2014, brings 21 years of experience across manufacturing operations, finance, regulatory compliance, and information technology within the pharmaceutical and consulting sectors. He holds a Bachelor of Engineering in IT from Mumbai University and an MBA in Finance and Marketing from the University of Florida's Warrington College of Business Administration.

During his tenure as CFO, Adhish Patil managed financial operations, enterprise resource planning (ERP) systems, and technical functions for the company. His upcoming appointment as Managing Director remains subject to shareholder approval at the company's upcoming Annual General Meeting.

In tandem with Patil's elevation, Rashesh C. Gogri—who has served as Managing Director since September 2014—has been elevated to Chairman, effective October 1, 2026. The board also accepted the retirement request of long-serving Whole-time Director Uday M. Patil and approved the appointment of Nilesh B. Patil as Whole-time Director for a five-year term starting at the conclusion of the upcoming Annual General Meeting.

Reconstitution of Key Board Committees

To align governance structures with the executive shifts, the Board of Directors approved the reconstitution of several key committees effective October 1, 2026:

• Audit Committee: Chaired by Independent Director Hasmukh B. Dedhia, with Rashesh C. Gogri and Adhish P. Patil serving as members alongside independent directors.

• Nomination and Remuneration Committee: Led by Independent Director Neha R. Gada.

• Risk Management Committee: Chaired by Rashesh C. Gogri, with Adhish P. Patil, Harshit M. Savla, and Nilesh B. Patil joining key operations executives.

• Corporate Social Responsibility Committee: Led by Independent Director Bhaskar N. Thorat.

• Finance and Investment Committee: Chaired by Rashesh C. Gogri, with Adhish P. Patil serving as a member.

The company confirmed to the BSE and National Stock Exchange of India (NSE) that none of the appointed directors are debarred from holding office by SEBI or any other regulatory authority.

Official Sources Section

According to official regulatory filings submitted to BSE Limited and the National Stock Exchange of India Limited (NSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

• The Board of Directors met on July 31, 2026, from 2:30 PM to 5:20 PM IST to consider and approve the leadership transition.

• Prakash M. Patil expressed his desire to seek early retirement to ensure a seamless leadership handoff.

• All proposed board appointments and re-appointments will be submitted for shareholder approval at the ensuing Annual General Meeting.

Quote Section

According to official disclosures filed with stock exchanges, the board expressed deep gratitude for the outgoing chairman's tenure:

"The Board accepted his request with deep appreciation and gratitude for his visionary leadership, unwavering commitment and invaluable contribution to the Company over the years and wished him good health, happiness and success in his future endeavours," the company stated in its filing. The board further requested that Prakash M. Patil continue his association with the firm to provide strategic guidance during the transition period.

Why It Matters

For investors, market analysts, and corporate stakeholders, the leadership succession at Aarti Drugs Limited signals strategic continuity within one of India's established active pharmaceutical ingredient (API) and bulk drug manufacturers. Elevating experienced internal executives like Adhish Patil and Rashesh Gogri ensures operational stability while updating corporate governance structures to support long-term growth and regulatory compliance.

Key Facts at a Glance

• Executive Transition: Adhish P. Patil appointed Managing Director for 5 years effective October 1, 2026, subject to shareholder approval.

• Chairman Elevation: Current MD Rashesh C. Gogri elevated to Chairman starting October 1, 2026, maintaining dual responsibilities.

• Outgoing Leadership: Prakash M. Patil retires as Chairman and CEO on September 30, 2026, after serving as Chairman since 2014.

• New Board Member: Nilesh B. Patil appointed as Whole-time Director for a 5-year term, replacing retiring director Uday M. Patil.

Frequently Asked Questions (FAQ)

Who was appointed as the new Managing Director of Aarti Drugs?

Adhish P. Patil, current Chief Financial Officer, was appointed as Managing Director for a five-year term beginning October 1, 2026, subject to shareholder approval.

Why is Prakash M. Patil stepping down as Chairman and CEO?

Prakash M. Patil opted for early retirement to facilitate an orderly and planned leadership transition within the company.

When do the new board appointments take effect?

The executive restructuring and committee reconstitutions take effect on October 1, 2026, following shareholder approvals at the upcoming Annual General Meeting.

Sources: Aarti Drugs Limited Official Corporate Filing, Company Disclosure to Stock Exchnages